SCHEMBL192610

SCHEMBL192610

O=C1CCc2cc(F)ccc21

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
HSD17B10 Q99714 1/20 0.59
HSD17B1 P14061 3/20 0.54
SRD5A1 P18405 2/20 0.53
GRM5 P41594 1/20 0.49
MAOB P27338 4/20 0.46
MAOA P21397 3/20 0.46
PRKCI P41743 1/20 0.46
CYP11B1 P15538 4/20 0.45
CYP11B2 P19099 4/20 0.45
CYP19A1 P11511 4/20 0.45
CYP1A2 P05177 1/20 0.45
PTGS2 P35354 1/20 0.44
PBRM1 Q86U86 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29726050 1.00 CASP1 (0.59) CASP1CASP7HSD17B10HSD17B1SRD5A1
SCHEMBL315877 0.88 MAOA (0.61) CASP1CASP7HSD17B10HSD17B1SRD5A1
SCHEMBL2585151 0.88 MAOA (0.59) CASP1CASP7HSD17B10HSD17B1SRD5A1
SCHEMBL3372953 0.84 SRD5A1 (0.54) SRD5A1CYP11B1CYP11B2CYP19A1
SCHEMBL1745120 0.84 HSD17B1 (0.69) CASP1CASP7HSD17B10HSD17B1GRM5
SCHEMBL1150109 0.83 PBRM1 (0.59) CASP1CASP7HSD17B10HSD17B1SRD5A1
SCHEMBL29443089 0.83 PBRM1 (0.59) CASP1CASP7HSD17B10HSD17B1SRD5A1
SCHEMBL8598463 0.82 CA1 (0.47) CASP1CASP7HSD17B10HSD17B1SRD5A1
SCHEMBL9791679 0.78 NOTUM (0.51) CASP1CASP7HSD17B10HSD17B1SRD5A1
SCHEMBL8251126 0.78 MAPK14 (0.55) SRD5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 946 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861113-B Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2022-12-06 CN claimed
CN-113861113-A Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2021-12-31 CN claimed
CN-111253260-A Synthesis method of β -tertiary alcohol ester compound 赣南医学院 2020-06-09 CN claimed
EP-2459540-A2 PREPARATION OF FIPAMEZOLE Dr. Reddy's Laboratories, Ltd. (IN) 2012-06-06 EP claimed
US-20120130084-A1 PREPARATION OF FIPAMEZOLE DR. REDDY'S LABORATORIES, INC. (US) 2012-05-24 US claimed
WO-2011014613-A2 PREPARATION OF FIPAMEZOLE DR. REDDY'S LABORATORIES LTD. (IN) 2011-02-03 WO claimed
US-20090197167-A1 Fluorinated Additives For Lithium Ion Batteries SOLVAY FLUOR GMBH (DE) 2009-08-06 US claimed
EP-1938404-A1 FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES Solvay Fluor GmbH (DE) 2008-07-02 EP claimed
WO-2007042471-A1 FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES SOLVAY FLUOR GMBH (DE) 2007-04-19 WO claimed
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 US disclosed
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2026-05-07 US disclosed
EP-4735449-A1 TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE OmniAB, Inc. (US) 2026-05-06 EP disclosed
EP-3964518-B1 CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2026-01-28 EP disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
EP-0247724-A1 Thiadiazinon derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1987-12-02 EP disclosed
EP-0199845-A1 Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them HEUMANN PHARMA GMBH & CO (DE) 1986-11-05 EP disclosed
US-4537892-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1985-08-27 US disclosed
EP-0137333-A2 Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase ALCON LABORATORIES, INC. (US) 1985-04-17 EP disclosed
EP-0009554-B1 INDANYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS SCHERING AKTIENGESELLSCHAFT (DE) 1983-04-27 EP disclosed
US-4244960-A HERBICIDES OR ANTIINFLAMMATORY AGENTS SCHERING, AKTIENGESELLSCHAFT (DE) 1981-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 CASP1 2108/4885CASP7 1745/4885HSD17B10 169/4885
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX CASP1 21/4885CASP7 17/4885HSD17B10 571/4885
US-20120130084-A1 PREPARATION OF FIPAMEZOLE FIP1L1, CYP3A7, CYP3A4 CASP1 2835/4885CASP7 850/4885HSD17B10 1282/4885
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC3, HDAC1 CASP1 4174/4885CASP7 3265/4885HSD17B10 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.